SUNDAY, FEBRUARY 21

Arrival and Registration

MONDAY, FEBRUARY 22

Welcome and Keynote Address

Pamela J. Bjorkman, California Institute of Technology, USA
A Molecular Arms Race: The Immune System versus HIV

Human Immunization

William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Clinical Tests of Germline Targeting

Julie Ledgerwood, NIAID, National Institutes of Health, USA
VRC01 Clinical Trials

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Env based Immunogenicity in the Clinic

Short Talks Chosen from Abstracts

Passive Therapies

Glenda E. Gray, South African Medical Research Council, South Africa
The AMP Study

Marina F. Caskey, Rockefeller University, USA
Human Studies with Combination bNAbs

Katharine Bar, University of Pennsylvania, USA
Treatment Interruption after bNAb Administration

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, FEBRUARY 23

Vaccine Immunology

Speaker to be Announced

Speaker to be Announced

Gabriel D. Victora, Rockefeller University, USA
Germinal Center Dynamics

Facundo D. Batista, MIT and Harvard University, USA
Mouse Models for HIV-1 Vaccines

Short Talks Chosen from Abstracts

Immunization Strategies

Neil P. King, University of Washington, USA
Design of Self-Assembling Protein Nanomaterials for Structure-Based Vaccine Design

Shane Crotty, La Jolla Institute for Immunology, USA
Increasing the Breadth and Potency of Candidate HIV Vaccine Immunogenic Responses

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Adjuvants in HIV-1 Vaccination

Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 24

HIV Immunology

Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Viral vs. Antibody Diversification during Infection

Alexandra Trkola, University of Zürich, Switzerland
Role of the Virus in Dictating the Immune Response

Beatrice H. Hahn, University of Pennsylvania, USA
Exploiting the Ape Precursors of HIV-1 for AIDS Vaccine Design

Catherine A. Blish, Stanford University School of Medicine, USA
Targeting Natural Killer Cells to HIV

Short Talks Chosen from Abstracts

Control of Latency

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
The Nature of the Latent Reservoir

Mary Carrington, NCI, National Institutes of Health, USA
Immunogenetic Variation in Outcome to HIV Therapy

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
How Elite Controllers Control

Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, FEBRUARY 25

Cure Related Human Trials

Malcolm A. Martin, National Institutes of Health, USA
Antibody Studies in SHIV Infected Macaques

Romas Geleziunas, Gilead Sciences, Inc., USA
Developing Combination Therapies for Cure

Sharon R. Lewin, University of Melbourne, Australia
The Latent Reservoir

Sarah Fidler, Imperial College Faculty of Medicine, UK
Clinical Interventions and their Effects on Viral Rebound

Short Talks Chosen from Abstracts

Session Title to be Determined

Peter D. Kwong, NIAID, National Institutes of Health, USA
HIV-1 Vaccination Targeting Specific Sites of Vulnerability

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
SOSIP based Immunogens as Vaccines

Christopher O. Barnes, California Institute of Technology, USA
Structures of HIV-1 Env Trimers Define Antibody-Mediated Neutralization of HIV-1

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, FEBRUARY 26

Departure